Bansisons Tea Industries Ltd bansisons tea industries has updated its official website address to reflect its current corporate identity as Novyra Pharmachem Limited. The company announced on August 4, 2026, that its digital disclosures and investor information are now hosted at www.novyrapharmachemltd.com , replacing the former domain www.bansisonstea.com . This change ensures that shareholders and stakeholders can access material information through a platform that accurately represents the company’s present name and business focus.

The intimation was submitted to BSE Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing confirms that all statutory disclosures required under Regulation 46 of the same regulations are now available on the new website. The move is part of the company’s broader transition following its name change from Bansisons Tea Industries Ltd to Novyra Pharmachem Limited.

Website Transition Details

The company provided specific details regarding the change in digital infrastructure:

Anil M. Amreliya, Director of Novyra Pharmachem Limited, signed the intimation filed with the exchange. The company requested BSE Limited to update its records accordingly to ensure that investors are directed to the correct source for official communications.

Regulatory Compliance

Under Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities must host specific disclosures on their websites, including financial results, annual reports, and other material events. By migrating these disclosures to the new domain, Novyra Pharmachem Limited maintains its compliance obligations without disruption. The old website address is no longer the primary channel for such information.

What the Numbers Show

While this announcement does not contain financial metrics, it signals a structural alignment between the company’s legal identity and its public-facing communications. The shift from a tea-industry-focused domain to one reflecting "Pharmachem" underscores the strategic pivot implied by the name change. Investors should note that all future regulatory filings and investor relations materials will be accessible exclusively through the new portal, ensuring consistency in information dissemination.

Novyra Pharmachem Limited (Formerly known as Bansisons Tea Industries Limited) secured shareholder approval for its Scheme of Capital Reduction during the 39th Annual General Meeting held on June 25, 2026. The meeting, conducted via video conferencing, saw the passage of all five resolutions with requisite majority, including the re-appointment of a director and the regularization of Anilkumar Amreliya as Executive Director and Managing Director.

The voting process, managed by National Securities Depository Limited (NSDL), recorded participation from 45 members through remote e-voting. While 35 members attended the meeting, votes were cast primarily via the remote e-voting facility which was open from June 22 to June 24, 2026. Mrs. Rupal Patel, Practicing Company Secretary, served as the Scrutinizer to ensure the fairness and transparency of the process.

Voting Results Summary

The resolutions were passed with the support of public non-institutional shareholders, while promoter group shares recorded zero votes. The special resolution regarding the capital reduction scheme received 98.53% approval, with 5,41,500 shares in favour and 8,100 shares against.

Key Appointments

Shareholders approved the regularization of Anilkumar Amreliya (DIN: 11339148) as Executive Director and his appointment as Managing Director. Additionally, Mr. Sandeep Agarwal (DIN: 00688647), who retired by rotation, was re-appointed to the Board. The total number of shareholders on the record date of June 18, 2026, stood at 27,858.